DUBLIN–(BUSINESS WIRE)–The “3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
The “3D Cell Culture Market” report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of the market in the mid to long term. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain.
At present, more than 140 companies offer 3D cell culture systems in a variety of formats, including scaffold-based products, scaffold-free products and 3D bioreactors.
These systems have demonstrated to be capable of more accurately simulating the natural tissue microenvironment, offer increased cell-to-cell and cell-to-ECM interactions, more accurate evaluation of drug toxicity and cellular responses, and co-cultuirng of multiple cell types together.
Moreover, there are certain complex 3D cell culture models that can even replace animal models exhibiting reproducible results and thereby, serving as better in vivo models across multiple application areas. Given the various benefits of such systems, the field has garnered the attention of various venture capital firms and strategic investors that have been providing financial support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ-on-chips across multiple application areas.
Moreover, there has been an increase in scientific literature on 3D cell culture systems and collaborations for 3D bioreactors and cell culture products. Given the ongoing innovation in this field, and the paradigm shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness a significant growth in the foreseen future.
Scope of the Report
Amongst other elements, the report includes:
- A detailed discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
- An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
- An overview of the current market landscape of companies offering various 3D cell culture systems, including information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
- A detailed assessment of the overall landscape of scaffold based products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of scaffold (human based, chemical based, animal based, plant based, and polymer based), and fabrication material used. In addition, it presents details of the companies involved in the development of scaffold based products, providing information on their year of establishment, company size, and location of headquarters.
- A detailed assessment of the overall landscape of scaffold free products, along with analyses based on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), type of material (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies involved in the development of scaffold free products, providing information on their year of establishment, company size, and location of headquarters.
- A detailed assessment of the overall landscape of 3D bioreactors, along with analyses based on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), status of development (under development, developed and not commercialized, and commercialized), typical working volume, scale of operation (lab scale, pre-clinical / clinical scale and commercial scale), type of manufacturing process (batch-continuous, fed-batch and continuous), type of cell culture system (mammalian cell, insect cell, microbial cell, and plant cell), type of molecule processed (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy and gene therapy), and application area (drug discovery / toxicity testing, stem cell research, regenerative medicine / tissue engineering and cancer research). In addition, it presents details of the companies involved in the development of 3D bioreactors, providing information on their year of establishment, company size, and location of headquarters.
- A detailed review of the key application areas (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
- Elaborate profiles of prominent players offering Scaffold-based, Scaffold-free cell culture systems and 3D bioreactors (shortlisted based on the number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile includes a brief overview of the company, financial / funding information (if available), details on its product portfolio, recent developments, and an informed future outlook.
- An analysis of the investments made in the period between 2016-2022, including instances of seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
.The report features detailed transcripts of interviews held with the following industry and non-industry players:
- Brigitte Angres (Co-founder, Cellendes)
- Bill Anderson (President and CEO, Synthecon)
- Anonymous (President and CEO, Anonymous)
- Anonymous (Co-founder and Vice President, Anonymous)
- Scott Brush (Vice President, BRTI Life Sciences)
- Malcolm Wilkinson (Managing Director, Kirkstall)
- Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
- Tanya Yankelevich (Director, Xylyx Bio)
- Jens Kelm (Chief Scientific Officer, InSphero)
- Walter Tinganelli (Group Leader, GSI)
- Darlene Thieken (Project Manager, Nanofiber Solutions)
- Andrea Picon (Director, Business Development, FlexCell International)
- Frank Junker (Chief Business Officer, InSphero)
- Mohammed Mamunur Rahman (Manager, Business Development, MBL International)
Key Questions Answered
- Who are the leading industry players engaged in the development of 3D cell culture products?
- Which are the most popular 3D cell culture products?
- Which are the different application areas for which 3D cell culture products are being developed?
- What are the key factors that are likely to influence the evolution of 3D cell culture systems market?
- What is the trend of capital investments in the 3D cell culture systems market?
- Which partnership models are commonly adopted by stakeholders in 3D cell culture market?
- How is the current and future opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to 3D cell culture systems market?
For more information about this report visit https://www.researchandmarkets.com/r/x84ihb
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900